Ligand Pharmaceuticals Inc. (NASDAQ:LGND) – Research analysts at Roth Capital dropped their Q3 2016 earnings per share estimates for shares of Ligand Pharmaceuticals in a research note issued on Sunday. Roth Capital analyst J. Pantginis now forecasts that the firm will post earnings of $0.06 per share for the quarter, down from their previous estimate of $0.12. Roth Capital has a “Buy” rating and a $150.00 price target on the stock. Roth Capital also issued estimates for Ligand Pharmaceuticals’ Q4 2016 earnings at $0.69 EPS.

A number of other research firms have also recently issued reports on LGND. Zacks Investment Research cut shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “sell” rating in a research report on Tuesday, October 4th. CJS Securities decreased their price objective on shares of Ligand Pharmaceuticals from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 28th. Vetr upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $128.29 price objective on the stock in a research report on Wednesday, August 10th. Deutsche Bank AG upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating and decreased their price objective for the company from $110.00 to $105.00 in a research report on Wednesday, September 7th. They noted that the move was a valuation call. Finally, TheStreet cut shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Ligand Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $139.25.

Ligand Pharmaceuticals (NASDAQ:LGND) opened at 98.32 on Tuesday. The company has a 50-day moving average of $107.51 and a 200 day moving average of $117.01. Ligand Pharmaceuticals has a 12 month low of $82.06 and a 12 month high of $139.79. The company has a market cap of $2.05 billion, a PE ratio of 9.27 and a beta of 1.23.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.10. Ligand Pharmaceuticals had a net margin of 263.14% and a return on equity of 11.64%. The business had revenue of $19.50 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter last year, the firm earned $1.81 EPS. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year.

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Ligand Pharmaceuticals by 8.0% in the second quarter. Vanguard Group Inc. now owns 1,515,814 shares of the biotechnology company’s stock valued at $180,790,000 after buying an additional 111,807 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Ligand Pharmaceuticals by 6.5% in the second quarter. BlackRock Fund Advisors now owns 1,466,467 shares of the biotechnology company’s stock valued at $174,906,000 after buying an additional 89,463 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Ligand Pharmaceuticals by 2.1% in the second quarter. William Blair Investment Management LLC now owns 1,255,277 shares of the biotechnology company’s stock valued at $149,717,000 after buying an additional 25,825 shares in the last quarter. FMR LLC increased its position in shares of Ligand Pharmaceuticals by 8.2% in the second quarter. FMR LLC now owns 1,055,463 shares of the biotechnology company’s stock valued at $125,885,000 after buying an additional 80,200 shares in the last quarter. Finally, State Street Corp increased its position in shares of Ligand Pharmaceuticals by 5.3% in the second quarter. State Street Corp now owns 737,003 shares of the biotechnology company’s stock valued at $87,904,000 after buying an additional 37,215 shares in the last quarter.

In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 1,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $137.57, for a total value of $137,570.00. Following the sale, the director now owns 41,783 shares in the company, valued at $5,748,087.31. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John W. Kozarich sold 1,666 shares of the company’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $105.40, for a total transaction of $175,596.40. Following the completion of the sale, the director now owns 40,783 shares in the company, valued at approximately $4,298,528.20. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by company insiders.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

5 Day Chart for NASDAQ:LGND

Receive News & Stock Ratings for Ligand Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.